Cue Biopharma (CUE) Debt to Equity (2022 - 2025)
Cue Biopharma's Debt to Equity history spans 4 years, with the latest figure at $0.12 for Q3 2025.
- On a quarterly basis, Debt to Equity fell 40.35% to $0.12 in Q3 2025 year-over-year; TTM through Sep 2025 was $0.12, a 40.35% decrease, with the full-year FY2024 number at $0.25, up 12.47% from a year prior.
- Debt to Equity hit $0.12 in Q3 2025 for Cue Biopharma, down from $0.14 in the prior quarter.
- Over the last five years, Debt to Equity for CUE hit a ceiling of $0.51 in Q1 2025 and a floor of $0.12 in Q3 2025.
- Historically, Debt to Equity has averaged $0.22 across 4 years, with a median of $0.21 in 2024.
- The widest YoY moves for Debt to Equity: up 113.72% in 2025, down 50.64% in 2025.
- Tracing CUE's Debt to Equity over 4 years: stood at $0.15 in 2022, then skyrocketed by 44.64% to $0.22 in 2023, then rose by 12.47% to $0.25 in 2024, then tumbled by 49.75% to $0.12 in 2025.
- Business Quant data shows Debt to Equity for CUE at $0.12 in Q3 2025, $0.14 in Q2 2025, and $0.51 in Q1 2025.